Table 1.
The basic information of the 17 RCTs of PNS on CAD.
| Study ID | Sample(T/C) | Age, Mean ± SD T,y | Age, Mean ± SD C,y | M/F T | M/F C | Intervention group | Course (weeks) | Control group | Outcome measures | References |
|---|---|---|---|---|---|---|---|---|---|---|
| Du, 2009 | 56/56 | 58.8 ± 9.2 | 58.8 ± 9.2 | Unclear | Unclear | XST + conventional drugs | 4 | Conventional drugs | FAA, DAA, DN | Du and Chen, 2009 |
| Feng, 2016 | 36/35 | 69.3 ± 4.8 | 69.4 ± 5.2 | 21/15 | 20/15 | PNS | 12 | Atorvastatin | lipid, PEP | Feng et al., 2016 |
| Han, 2008 | 30/30 | 64.1 ± 10.8 | 63.7 ± 11.7 | 23/7 | 21/9 | XST + conventional drugs | 12 | Conventional drugs | FAA, DAA | Han, 2008 |
| Hou, 2016 | 42/42 | 62.3 ± 2.31 | 62.4 ± 2.32 | 23/19 | 22/20 | XST + conventional drugs | 4 | Conventional drugs | FAA, DAA, ECG | Hou, 2016 |
| Kong, 2006 | 52/52 | 61.2 ± 5.73 | 60.77 ± 5.61 | 31/21 | 32/20 | XST + conventional drugs | 4 | Conventional drugs | FAA, ECG | Kong and Zhang, 2006 |
| Kuang, 2011 | 90/90 | 56.3 ± 6.9 | 57.1 ± 7.2 | 47/43 | 46/44 | XST + conventional drugs | 4 | Conventional drugs | FAA, DAA | Kuang et al., 2011 |
| Liu, 2008 | 30/30 | 64.6 ± 5.4 | 63.6 ± 4.5 | Unclear | Unclear | XST + conventional drugs | 4 | Conventional drugs | ECG, lipid | Liu et al., 2008 |
| Meng, 2013 | 600/600 | 68 ± 11 | 69 ± 9 | 421/179 | 368/232 | PNS tablet + conventional drugs | 52 | Conventional drugs | PEP | Meng et al., 2013 |
| Song, 2005 | 50/50 | 61.2 ± 5.73 | 60.8 ± 5.61 | 31/19 | 33/17 | XST + conventional drugs | 4 | Conventional drugs | FAA, DN, ECG | Song et al., 2005 |
| Teng, 2014 | 40/40 | 70.7 ± 6.87 | 71.7 ± 4.32 | 17/23 | 21/19 | XST + conventional drugs | 4 | Conventional drugs+XST capsule placebo | FAA, lipid | Teng, 2014 |
| Wan, 2011 | 26/26 | 65.7 | Unclear | 15/11 | 13/13 | XST + conventional drugs | 4 | Conventional drugs | ECG | Wan, 2011 |
| Wei, 2010 | 90/90 | 60.4 ± 3.5 | 60.4 ± 3.5 | Unclear | Unclear | XST +conventional drugs | 4 | Conventional drugs | FAA, DAA | Wei, 2010 |
| Yan, 2015 | 28/27 | 76.3 ± 9.04 | 76.32 ± 9.04 | Unclear | Unclear | Sanqi Tongshu capsule +aspirin | 24 | Aspirin | PEP | Yan et al., 2015 |
| Yu, 2010 | 50/50 | 64.2 ± 12.13 | 62.8 ± 10.8 | 29/21 | 28/22 | XST + conventional drugs | 4 | Conventional drugs | ECG | Yu, 2010 |
| Zhang, 2014 | 30/30 | 60 ± 3.4 | 61 ± 4.0 | 16/14 | 15/15 | XST + trimetazidine | 4 | Trimetazidine | FAA, DAA | Zhang, 2014 |
| Zheng, 2014 | 56/56 | Unclear | Unclear | Unclear | Unclear | XST + conventional drugs | 4 | Conventional drugs | ECG | Zheng, 2014 |
| Zhou, 2009 | 43/43 | 65 ± 6 | 65 ± 6 | 32/11 | 34/9 | XST + conventional drugs | 4 | Conventional drugs | ECG | Zhou and Bai, 2009 |
T/C, Treatment group/control group; M/F, Male/female; XST, Xuesaitong soft capsule; FAA, frequency of angina attack; DAA, duration of angina attack; DN, dosage of nitroglycerin; PEP, the primary end point.